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Abstract
We examined the individual and synergistic effects of type 2 diabetes and elevated depres-
sive symptoms on memory and executive function trajectories over 10 and eight years of fol-
low-up, respectively. Our sample comprised 10,524 community-dwellers aged50 years in
2002–03 from the English Longitudinal Study of Ageing. With respect to memory (word
recall), participants with either diabetes or elevated depressive symptoms recalled signifi-
cantly fewer words compared with those free of these conditions (reference category), but
more words compared with those with both conditions. There was a significant acceleration
in the rate of memory decline in participants aged 50–64 years with both conditions (-0.27,
95% CI, -0.45 to -0.08, per study wave), which was not observed in those with either condi-
tion or aged65 years. With respect to executive function (animal naming), participants
aged65 years with diabetes or those with elevated depressive symptoms named signifi-
cantly fewer animals compared with the reference category, while those with both conditions
named fewer animals compared with any other category. The rate of executive function
decline was significantly greater in participants with both conditions (-0.54, 95% CI, -0.99 to
-0.10; and –0.71, 95% CI, -1.16 to -0.27, per study wave, for those aged 50–64 and65
years, respectively), but not in participants with either condition. Diabetes and elevated
depressive symptoms are inversely associated with memory and executive function, but,
individually, do not accelerate cognitive decline. The co-occurrence of diabetes and ele-
vated depressive symptoms significantly accelerates cognitive decline over time, especially
among those aged 50–64 years.
Introduction
Depression is almost twice as common in type 2 diabetes mellitus (hereafter diabetes) patients
compared with people free of diabetes [1]. The relationship between diabetes and depression
appears to be bidirectional [2,3] with depression increasing the risk of incident diabetes [3,4]
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and diabetes increasing the risk of subsequent depression [5,6]. Recent findings expands on
this evidence and suggest that the bidirectional association is age dependent with diagnosed
diabetes being associated with subsequent elevated depressive symptoms in people aged 52 to
64 years, but not those aged65 years [7]. Both diabetes and depression are associated with
increased risk of cognitive decline and dementia [8–16].
Despite the close relationship between diabetes and depression and their importance for
cognition, few prospective studies have examined the combined effect of diabetes and depres-
sion on cognitive decline and dementia. Two studies found that comorbid depression was
associated with a 2- to 3-fold increased risk of developing dementia in people with diabetes
[17,18], while a large-scale study that used data from national registries found the combined
effect of diabetes and depression on dementia risk to be greater than the sum of their individ-
ual effects [19]. With respect to cognitive decline, a study reported that diabetes patients with
comorbid depression experienced a greater cognitive decline compared with those without
depression over 40-month follow-up [20]. A recent study of community-dwelling Mexican
Americans aged65 years found that comorbid depression and diabetes were associated with
worse cognitive performance over an 11-year follow-up [21].
We used a national sample of community-dwelling individuals aged50 years to investi-
gate the associations between baseline diabetes and elevated depressive symptoms and trajecto-
ries of cognitive function over a 10-year follow-up. We examined differences in the risk of
cognitive decline as well as the rate of cognitive decline according to baseline diabetes and ele-
vated depressive symptoms with people with both conditions constituting a separate category.
Research design and methods
Study population
The sample comes from the English Longitudinal Study of Ageing (ELSA), a prospective
observational study of community-dwelling people aged50 years in England, and was
recruited using a multistage stratified random probability design. The baseline interview took
place in 2002–03 and sample comprised 11,391 individuals. After the baseline, follow-up inter-
views took place biennially. All waves and parts of ELSA have been approved by the national
Research Ethics Service (http://www.hra.nhs.uk/about-the-hra/our-committees/res/) and
informed consent has been obtained by the participants after they were informed in writing
and in advance about the study and its purpose. Written informed consent was sought for spe-
cific parts of the study including the health examination; for the interview the informed con-
sent was verbal.
A detailed description of the study can be found at: http://www.elsa-project.ac.uk/. The
analytical sample comprised 10,524 participants who were present at baseline, after the exclu-
sion of 362 participants with proxy or partial interviews, 63 possible cases of type 1 diabetes i.e.
age at self-reported diabetes diagnosis40 years, 44 cases of self-reported dementia and Alz-
heimer’s disease, and 398 participants with missing values in baseline variables (excluding
BMI).
Assessment of cognitive function
We assessed two domains of cognitive function: memory and executive function. We measured
two dimensions of memory, immediate and delayed recall, using a 10-word test that has earlier
been used in the Health and Retirement Study (HRS) [22]. Participants were asked to listen to a
list of 10 words and immediately recall as many as they could. Few minutes later, without prior
notice and after they had engaged in other tasks, they were asked again to recall as many words
as they could. Because the associations between diabetes and elevated depressive symptoms and
Type 2 diabetes, depressive symptoms and trajectories of cognitive decline
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immediate and delayed recall scores followed similar patterns and our objective was to examine
the overall effect of comorbid depression and diabetes on memory decline, we combined the
two recall scores to generate a recall summary score (range: 0 to 20 words), which we then used
in our analyses. We assessed executive function using a semantic verbal fluency test, which
involved naming as many animals as one could in 60 seconds [22]. At baseline, the animal nam-
ing score ranged from 0 to 50 words. Word recall ability was measured at baseline and all five
follow-up interviews, and animal naming at baseline and the first four follow-up interviews. To
minimise non-response bias, we imputed the missing values in both cognitive scores using
chained equations in STATA 14. The imputed data were censored at the date of death. The anal-
yses were based on 57,199 observations of recall score of which 14,652 were imputed and 48,791
observations of animal naming score of which 11,375 were imputed.
Assessment of diabetes and elevated depressive symptoms
We measured depressive symptoms at baseline using the eight-item Center for Epidemiologi-
cal Studies-Depression (CES-D) scale [23]. We derived a CES-D summary score by adding up
responses to all eight dichotomous questions. To generate a variable of elevated depressive
symptoms, we dichotomized the CES-D summary score using the cut point of4, which cor-
responds to the cut point of16 on the 20-item CES-D [23]. We also measured self-reported
doctor-diagnosed diabetes at baseline. We were able to validate baseline diabetes diagnosis for
8,081 of our participants using diabetes medication data that predated the baseline (they were
measured in 1998 or 2001). We combined information on diabetes and elevated depressive
symptoms to derive the main exposure variable with the following categories: 1) without dia-
betes and elevated depressive symptoms, 2) without elevated depressive symptoms, but with
diabetes, 3) with elevated depressive symptoms, but without diabetes, and 4) with both diabe-
tes and elevated depressive symptoms.
Covariates
Age, sex, marital status, education, and occupational class, self-reported doctor-diagnosed
chronic conditions (i.e. heart disease, stroke, hypertension, and chronic lung disease), smok-
ing, physical activity, alcohol consumption, and measured body mass index (BMI) were used
in the analyses. All covariates were measured at baseline in 2002–03, except for BMI, which
calculation was based on height and weight measurements that were taken by nurses in 1998,
1999 or 2001. To avoid unnecessarily excluding from our analyses a large number of partici-
pants with missing BMI values (n = 1062), we imputed missing BMI values.
Statistical analysis
We analysed the baseline characteristics of the sample according to diabetes and elevated depres-
sive symptoms status. We estimated a linear mixed (random coefficient) model of the association
between the exposure and six repeated measurements of word recall over a 10-year follow-up
that was gradually adjusted for covariates. Time was measured using a variable that reflected the
chronological order of the six repeated measurements (study waves) i.e. t = 1, 2, 3, 4, 5, 6. To
explore whether baseline diabetes and elevated depressive symptoms accelerated memory decline
over time, we also estimated a model that included the interaction term exposuretime. The same
modelling approach was employed when analysing the association between the exposure and five
repeated measurements of animal naming score over eight years of follow-up. Because the associ-
ation between diabetes and elevated depressive symptoms varied by age in our data [7] and we
found that the association between the predictor and memory, but not executive function, varied
by age, we stratified our analyses by age into two groups: 50–64 and65 years. The use of 65
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years as a cut point was decided on an empirical basis i.e. was the mean age of the sample, used to
be the national pension age for men, and resulted in two groups of similar size. For comparison
reasons, we performed additional analyses where we exclusively used the observed data (see
Tables A-D in S1 File).
Results
Participants with both diabetes and elevated depressive symptoms were more likely to be of
lower socioeconomic status, physically inactive, and obese and less likely to consume alcohol
and be married. Participants with diabetes, but without elevated depressive symptoms, were
more likely to be older, male and have hypertension, while those with elevated depressive
symptoms, but without diabetes, were more likely to be female and current smokers (Table 1).
The memory and executive function of participants with both diabetes and elevated depres-
sive symptoms at baseline significantly deteriorated over time compared with the reference
category (Figs 1 and 2), except for memory among those aged65 years.
In terms of memory, participants aged 50–64 years with both conditions recalled on average
1.25 fewer words (95% CI, -1.83 to -0.68) compared with the reference category after adjust-
ment for covariates. The respective estimate for participants aged65 years was 0.74 fewer
words (95% CI, -1.28 to -0.20) (Table 2). In both age groups, participants with either condition
did better than those with both conditions, but significantly worse compared with the refer-
ence category. There was a significant acceleration in the rate of memory decline in partici-
pants aged 50–64 years with both diabetes and elevated depressive symptoms (-0.27; 95% CI,
-0.45 to -0.08, per study wave) compared with the reference category, which was not observed
in those with either condition or aged65 years (Table 2).
With respect to executive function, participants aged 50–64 years with both conditions on
average named 1.73 fewer animals (95% CI, -2.94 to -0.51) compared with the reference cate-
gory after adjustment for covariates, while those aged65 years with both conditions named
1.60 fewer animals (95% CI, -2.57 to -0.63) (Table 3). Participants with elevated depressive
symptoms, and those aged65 years with diabetes, also named significantly fewer animals
compared with the reference category after adjustment for covariates. In both age groups, the
rate of executive function decline was significantly greater in participants with both conditions
compared with the reference category (-0.54; 95% CI, -0.99 to -0.10; and -0.71; 95% CI, -1.16
to -0.27, per study wave, for those aged 50–64 and65 years, respectively), but not those with
either diabetes or elevated depressive symptoms (Table 3).
Discussion
In a national sample of community-dwelling people aged50 years we found that the co-
occurrence of diabetes and elevated depressive symptoms exerts a synergistic effect on cogni-
tive ability and accelerates cognitive decline over time. Participants with either diabetes or ele-
vated depressive symptoms also performed worse on both tests compared with participants
who were free of these conditions, but their cognitive ability did not decline any faster.
To our knowledge our study is the first to examine the synergistic effect of diabetes and ele-
vated depressive symptoms on cognitive decline in a national sample of community-dwelling
people aged50 years. Our findings concur with findings suggesting that the combination of
diabetes and depression is prospectively associated with greater cognitive decline in diabetes
patients [20] and an increased risk of dementia in diabetes patients [17,18] and the general
population [19], but are at odds with those of a study of 570 diabetes patients and controls that
did not find any difference in the cognitive performance of diabetes patients according to ele-
vated depressive symptoms [24]. They also partially concur with the findings of a recent study
Type 2 diabetes, depressive symptoms and trajectories of cognitive decline
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Table 1. The baseline characteristics of 10524 women and men aged50 years by type 2 diabetes and elevated depressive symptoms.
Without diabetes and
elevated depressive
symptoms (n = 8275)
With diabetes, but
without elevated
depressive (n = 554)
Without diabetes, but with
elevated depressive
symptoms (n = 1526)
With both diabetes and
elevated depressive
symptoms (n = 169)
P
valuea
Mean age, years, (SD) 64.4 (9.9) 68.4 (9.1) 65.9 (10.8) 67.4 (9.3) <0.001
Sex (%) <0.001
Male 3910 (47.3) 340 (61.4) 526 (34.5) 71 (42.0)
Female 4365 (52.7) 214 (38.6) 1000 (65.5) 98 (58.0)
Marital status (%) <0.001
Married 5784 (69.9) 398 (71.8) 779 (51.0) 78 (46.1)
Other 2491 (30.1) 156 (28.2) 747 (49.0) 91 (53.9)
Education (%) <0.001
A-level or higher 2562 (31.0) 135 (24.4) 281 (18.4) 25 (14.8)
Secondary or
equivalent
2563 (31.0) 156 (28.1) 377 (24.7) 34 (20.1)
No qualifications 3150 (38.0) 263 (47.5) 868 (56.9) 110 (65.1)
Occupational class
(%)
<0.001
Managerial and
professional
occupations
2644 (32.0) 164 (29.6) 304 (19.9) 26 (15.4)
Intermediate
occupations
2046 (24.7) 107 (19.3) 330 (21.6) 20 (11.8)
Semi-routine and
routine occupations
3585 (43.3) 283 (50.1) 892 (58.5) 123 (72.8)
Physical activity at
least once a week (%)
<0.001
Vigorous-intensity 2583 (31.2) 96 (17.3) 236 (15.5) 11 (6.5)
Moderate-intensity 4054 (49.0) 277 (50.0) 637 (41.7) 58 (34.3)
Mild-intensity 1020 (12.3) 108 (19.5) 356 (23.3) 50 (29.6)
Physically inactive 618 (7.5) 73 (13.2) 297 (19.5) 50 (29.6)
Smoking (%) <0.001
Current smoker 1378 (16.7) 80 (14.4) 408 (26.7) 33 (19.5)
Former smoker 3823 (46.2) 323 (58.3) 680 (44.6) 83 (49.1)
Never smoker 3074 (37.1) 151 (27.3) 438 (28.7) 53 (31.4)
Body mass indexb
(%)
<0.001
<25kg/m2 2311 (27.9) 76 (13.7) 406 (26.6) 18 (10.7)
25 to <30 kg/m2 3470 (41.9) 216 (39.0) 540 (35.4) 45 (26.6)
 30 kg/m2 1736 (21.0) 201 (36.3) 370 (24.2) 73 (43.2)
Missing 758 (9.2) 61 (11.0) 210 (13.8) 33 (19.5)
Frequency of alcohol
consumption (%)
<0.001
Daily or almost daily 2491 (30.1) 115 (20.8) 346 (22.7) 18 (10.6)
1–2 times a week or
monthly
3533 (42.7) 221 (39.9) 526 (34.5) 51 (30.2)
Never or almost
never
2251 (27.2) 218 (39.3) 654 (42.8) 100 (59.2)
Heart disease (%) <0.001
No 7856 (94.9) 464 (83.8) 1384 (90.7) 145 (85.8)
Yes 419 (5.1) 90 (16.2) 142 (9.3) 24 (14.2)
Stroke (%) <0.001
(Continued )
Type 2 diabetes, depressive symptoms and trajectories of cognitive decline
PLOS ONE | https://doi.org/10.1371/journal.pone.0175827 April 17, 2017 5 / 14
of 2,756 community-dwelling Mexican Americans aged65 years [21]. Like our study, this
study found that the co-existence of diabetes and depression is associated with greater cogni-
tive decline over time, but also that diabetes is associated with greater cognitive decline inde-
pendent of comorbid depression, which is something that we did not find in our data. We
hypothesise that the discrepancy between these findings and our findings is mostly related to
differences in the epidemiological profiles and other characteristics of the two samples as well
as the use of different outcome measures.
In our study, elevated depressive symptoms were inversely associated with both memory
and executive function. Although research tends to differentiate between early- and late-onset
depression as predictors of cognitive decline and dementia and the role of late-life depression
in cognitive decline and dementia remains unclear [15,16], in agreement with our findings, a
substantial body of literature suggests that elevated depressive symptoms and clinical depres-
sion are associated with poorer cognitive ability, dementia, and Alzheimer’s disease [13–16].
Our findings also concur with most [25,26] but not all earlier findings [27] suggesting that ele-
vated depressive symptoms on their own do not accelerate cognitive decline in older people.
Finally, we also found that diabetes is inversely associated with cognitive ability. This finding
agrees with those of a review and two meta-analyses [8–10], which indicate that people with
diabetes perform worse on multiple cognitive domains including memory and executive
function.
Individually, neither diabetes nor depression accelerated cognitive decline with differences
in both memory and executive function trajectories between participants with elevated depres-
sive symptoms or diabetes and those free of these conditions remaining stable over time. It is
noteworthy that the differences between participants with either condition and those free of
both conditions remained relatively stable even when the entire sample experienced a decline
in their cognitive ability i.e. the decline in memory that was experienced by all participants
aged65 years. Differences in the trajectories of cognitive ability between participants with
elevated depressive symptoms or diabetes and those free of these conditions appear to be set
earlier in life and carried over to older ages. The only category that experienced a significant
worsening in their cognitive function over time (with the exception of memory among those
65 years) was that of participants with both diabetes and elevated depressive symptoms,
which differences with the reference category got increasingly greater over time. Our findings
are suggestive of a synergistic effect of diabetes and depression on cognitive function that
Table 1. (Continued)
Without diabetes and
elevated depressive
symptoms (n = 8275)
With diabetes, but
without elevated
depressive (n = 554)
Without diabetes, but with
elevated depressive
symptoms (n = 1526)
With both diabetes and
elevated depressive
symptoms (n = 169)
P
valuea
No 8002 (96.7) 517 (93.3) 1428 (93.6) 147 (87.0)
Yes 273 (3.3) 37 (6.7) 98 (6.4) 22 (13.0)
Hypertension (%) <0.001
No 5414 (65.4) 196 (35.4) 881 (57.7) 66 (39.1)
Yes 2861 (34.6) 358 (64.6) 645 (42.3) 103 (60.9)
Chronic Lung
Disease (%)
<0.001
No 7830 (94.6) 512 (92.4) 1342 (87.9) 148 (87.6)
Yes 445 (5.4) 42 (7.6) 184 (12.1) 21 (12.4)
a P values were calculated using chi-square, Kruskal-Wallis and analysis of variance tests for categorical, ordinal and continuous covariates, respectively.
b The missing category was not used in the calculation of the P value
https://doi.org/10.1371/journal.pone.0175827.t001
Type 2 diabetes, depressive symptoms and trajectories of cognitive decline
PLOS ONE | https://doi.org/10.1371/journal.pone.0175827 April 17, 2017 6 / 14
accelerates cognitive decline over time and significantly adds to baseline differences. This syn-
ergistic effect is not present at baseline, but develops over time and possibly accelerates cogni-
tive decline by exacerbating pathological processes.
Numerous pathological processes and pathways might mediate the observed associations
with glycaemic control, low-grade chronic inflammation, and micro- and macro-vascular dis-
eases being particularly pertinent. Regarding hyperglycaemia, based on evidence [28], it is
plausible to assume that comorbid depression in diabetes results in poorer glycaemic control,
which over time leads to greater cognitive decline via chronic hyperglycaemia. Nevertheless,
recent reviews do not fully support a hyperglycaemia-related explanation for the inverse asso-
ciation between diabetes and cognition [29,30]. Peripheral inflammation can affect central
nervous system and activate central inflammatory processes in different ways [31]. The
Fig 1. The trajectories of memory (word recall summary score) by diabetes and elevated depressive symptoms among
participants aged 50 to 64 (top panel) and 65 years or older (bottom panel).
https://doi.org/10.1371/journal.pone.0175827.g001
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activation of central inflammatory processes might lead to alterations in brain morphology
and function, which, in turn, might be related to cognitive decline [32,33]. Vascular abnormal-
ities are also implicated in the associations between diabetes, and brain abnormalities and cog-
nitive dysfunction [8,34], while vascular disease links depression to cognitive impairment [15].
Diabetes and depression are established cardiovascular risk factors [35,36], and their co-occur-
rence can result in a multitude of vascular abnormalities, which over time can affect the brain
and lead to accelerated cognitive decline. Psychosocial stress, HPA axis dysregulation and ele-
vated levels of glucocorticoids might also be part of the mechanism that leads from diabetes
and depression to cognitive decline. Depression is a stress-related disorder [37] and diabetes is
strongly associated with psychosocial stress [38], while stress modulates brain function and
alters brain structure and likely is associated with cognitive deficits [15,37]. Further, our
Fig 2. The trajectories of executive function (animal naming score) by diabetes and elevated depressive symptoms
among participants aged 50 to 64 (top panel) and 65 years or older (bottom panel).
https://doi.org/10.1371/journal.pone.0175827.g002
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findings suggest that diabetes patients with comorbid depression experienced a greater cogni-
tive decline over time partially because they engaged in unhealthy behaviours such as physical
inactivity. Previous findings suggest that unhealthy behaviours do not explain the associations
between depression and cognitive decline [20] or dementia [18], but these findings come from
studies of diabetes patients, which are expected to be different in terms of unhealthy behav-
iours compared with the general population. Socioeconomic position is also very relevant to
the examined associations and explained a considerable part of them. The important role of
socioeconomic position in the observed associations highlights their life course dimension and
suggests that they can partially be a result of experiences of social disadvantage and lower
socioeconomic position at earlier stages of the life course.
Table 2. The prospective association between type 2 diabetes, elevated depressive symptoms and word recall summary score (memory) over 10
years in 10524 participants aged50 years.
Without diabetes and
elevated depressive
symptoms
With diabetes, but
without elevated
depressive
Without diabetes, but with
elevated depressive
symptoms
With both diabetes and
elevated depressive
symptoms
Participants aged 50 to 64 (n = 5512)
No. of participants 4493 187 761 71
Slope (rate of decline)a
Model 1b 1.00 (reference) -0.96 (-1.32 to -0.60)*** -1.19 (-1.39 to -0.99)*** -2.14 (-2.76 to -1.52)***
Model 2c 1.00 (reference) -0.84 (-1.20 to -0.47)*** -1.11 (-1.32 to -0.91)*** -2.04 (-2.66 to -1.42)***
Model 3d 1.00 (reference) -0.76 (-1.09 to -0.42)*** -0.77 (-0.96 to -0.58)*** -1.52 (-2.10 to -0.94)***
Model 4e 1.00 (reference) -0.65 (-0.98 to -0.31)*** -0.64 (-0.83 to -0.45)*** -1.25 (-1.83 to -0.68)***
Model 5f 1.00 (reference) -0.44 (-0.87 to 0.0001)* -0.63 (-0.88 to -0.39)*** -0.48 (-1.21 to 0.25)
Slope acceleration
(exposure*time
interaction)a
Model 5f 1.00 (reference) -0.07 (-0.17 to 0.03) -0.002 (-0.06 to 0.06) -0.27 (-0.45 to -0.08)**
Participants aged65 years (n = 5012)
No. of participants 3782 367 765 98
Slope (rate of decline)a
Model 1b 1.00 (reference) -0.64 (-0.94 to -0.34)*** -1.03 (-1.25 to -0.81)*** -1.57 (-2.13 to -1.00)***
Model 2c 1.00 (reference) -0.61 (-0.92 to -0.31)*** -1.01 (-1.22 to -0.79)*** -1.46 (-2.03 to -0.89)***
Model 3d 1.00 (reference) -0.49 (-0.77 to -0.20)*** -0.71 (-0.91 to -0.50)*** -1.01 (-1.56 to -0.47)***
Model 4e 1.00 (reference) -0.39 (-0.67 to -0.10)** -0.55 (-0.76 to -0.33)*** -0.74 (-1.28 to -0.20)**
Model 5f 1.00 (reference) -0.32 (-0.69 to 0.05) -0.39 (-0.66 to -0.13)** -0.53 (-1.20 to 0.15)
Slope acceleration
(exposure*time
interaction)a
Model 5f 1.00 (reference) -0.03 (-0.14 to 0.09) -0.06 (-0.13 to 0.01) -0.09 (-0.27 to 0.10)
a The estimates are β regression coefficient (95% confidence intervals)
b Model 1 is adjusted for age, sex and marital status
c Model 2 is adjusted for age, sex, marital status and self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease
d Model 3 is adjusted for age, sex, marital status, self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease,
education and occupational class
e Model 4 is adjusted for age, sex, marital status, self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease,
education, occupational class, physical activity, smoking, alcohol consumption, and body mass index
f Model 5 is adjusted for all covariates included in Model 4 plus adjustment for the exposure*time interaction term
*** p value0.001
** p value0.01
* p value0.05
https://doi.org/10.1371/journal.pone.0175827.t002
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The use of a large national sample of community-dwellers aged50 years makes our find-
ings more applicable to the general population of older people. The long follow-up of eight to
ten years and the use of repeated measurements allowed a thorough examination of the effect
of diabetes and elevated depressive symptoms on different domains of cognitive function. The
age stratification of our analyses led to an identification of significant age differences in the
examined associations, while the use of imputed data is expected to minimise the effect of
post-baseline non-response on our findings and reduce attrition bias [39].
Despite these advantages, our study has several weaknesses that need to be acknowledged.
ELSA achieved a baseline response rate of 70%, which is good, but nevertheless leaves space
Table 3. The prospective association between type 2 diabetes, elevated depressive symptoms and animal naming score (executive function) over
8 years in 10524 participants aged50 years.
Without diabetes and
elevated depressive
symptoms
With diabetes, but
without elevated
depressive
Without diabetes, but with
elevated depressive
symptoms
With both diabetes and
elevated depressive
symptoms
Participants aged 50 to 64 (n = 5512)
No. of participants 4493 187 761 71
Slope (rate of decline)a
Model 1b 1.00 (reference) -0.65 (-1.43 to 0.13) -2.01 (-2.43 to -1.59)*** -3.22 (-4.49 to -1.95)***
Model 2c 1.00 (reference) -0.49 (-1.28 to 0.30) -1.89 (-2.31 to -1.47)*** -3.07 (-4.35 to -1.79)***
Model 3d 1.00 (reference) -0.34 (-1.08 to 0.41) -1.27 (-1.67 to -0.87)*** -2.13 (-3.34 to -0.92)***
Model 4e 1.00 (reference) -0.25 (-0.99 to 0.50) -1.04 (-1.45 to -0.63)*** -1.73 (-2.94 to -0.51)**
Model 5f 1.00 (reference) -0.01 (-0.96 to 0.95) -0.95 (-1.45 to -0.44)*** -0.38 (-1.92 to 1.17)
Slope acceleration
(exposure*time
interaction)a
Model 5f 1.00 (reference) -0.09 (-0.36 to 0.17) -0.04 (-0.18 to 0.10) -0.54 (-0.99 to -0.10)*
Participants aged65 years (n = 5012)
No. of participants 3782 367 765 98
Slope (rate of decline)a
Model 1b 1.00 (reference) -0.94 (-1.47 to -0.41)*** -1.72 (-2.13 to -1.32)*** -2.97 (-3.99 to -1.95)***
Model 2c 1.00 (reference) -0.88 (-1.41 to -0.34)*** -1.66 (-2.07 to -1.26)*** -2.73 (-3.75 to -1.71)***
Model 3d 1.00 (reference) -0.69 (-1.20 to -0.18)** -1.22 (-1.61 to -0.82)*** -2.10 (-3.07 to -1.12)***
Model 4e 1.00 (reference) -0.53 (-1.04 to -0.02)* -0.91 (-1.31 to -0.52)*** -1.60 (-2.57 to -0.63)***
Model 5f 1.00 (reference) -0.28 (-0.95 to 0.40) -0.59 (-1.08 to -0.09)* -0.06 (-1.36 to 1.24)
Slope acceleration
(exposure*time
interaction)a
Model 5f 1.00 (reference) -0.12 (-0.34 to 0.11) -0.15 (-0.32 to 0.03) -0.71 (-1.16 to -0.27)**
a The estimates are β regression coefficient (95% confidence intervals)
b Model 1 is adjusted for age, sex and marital status
c Model 2 is adjusted for age, sex, marital status and self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease
d Model 3 is adjusted for age, sex, marital status, self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease,
education and occupational class
e Model 4 is adjusted for age, sex, marital status, self-reported chronic conditions i.e. heart disease, stroke, hypertension and chronic lung disease,
education, occupational class, physical activity, smoking, alcohol consumption, and body mass index
f Model 5 is adjusted for all covariates included in Model 4 plus adjustment for the exposure*time interaction term
*** p value0.001
** p value0.01
* p value0.05
https://doi.org/10.1371/journal.pone.0175827.t003
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for non-response bias to influence our findings. Further, the exclusion of older people who
were not community-dwellers at baseline is expected to reduce to an extent the applicability of
our findings to institutionalised older people. The use of self-reported doctor-diagnosed diabe-
tes, despite the partial validation of these data against diabetes medication data, might have led
to a misclassification of diabetes cases and bias to a minor extent our findings. The lack of data
on concomitant medication and history of depression and inability to adjust our models for
these factors is an additional limitation that might have influenced to some extent our findings.
The use of the shortened 8-item CES-D, which focuses on a limited number of depressive
symptoms that were experienced by the respondents during the week preceding their ELSA
interview and which statistical invariance between participants with and without diabetes has
not been established, is an additional limitation. The lack of baseline BMI data and subsequent
use of BMI data that predated the baseline interview is a minor limitation of our work, which
given the chronological proximity of the employed BMI data to the baseline is unlikely to
influence our findings in a meaningful way. Another minor limitation that pertains to the
non-experimental nature of our study is that the time interval between the immediate and
delayed recall tests is not fixed and fluctuations in this time interval might have affected partic-
ipants’ performance in the delayed recall test. Nevertheless, given the design of the ELSA cog-
nitive interview and the strict order of the cognitive tests, we are confident that fluctuations in
the time that elapsed between the two recall tests have not affected our findings in any notice-
able way. Finally, the use of a sample of community-dwellers precluded us from examining the
role of diabetes duration, severity and management in the observed associations.
The long-term effects of diabetes and elevated depressive symptoms on memory and execu-
tive function are significant, but rather small. Individually, neither elevated depressive symp-
toms nor diabetes accelerate cognitive decline over time. Conversely, the co-occurrence of
diabetes and elevated depressive symptoms accelerates cognitive decline, especially among
those aged 50–64 years. Future research should concentrate on explaining the biological mech-
anisms of the synergistic effect of comorbid depression and diabetes on cognition and identify-
ing therapeutic targets. There is also need to examine whether diabetes mediates the
association between early-onset depression and cognitive decline. Identifying and treating
people with comorbid diabetes and depression, especially those at the beginning of midlife,
should be a priority in clinical practice.
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